WO1998048000A3 - A cell strain with activated anti-cancer cytotoxic activity - Google Patents
A cell strain with activated anti-cancer cytotoxic activity Download PDFInfo
- Publication number
- WO1998048000A3 WO1998048000A3 PCT/US1998/008240 US9808240W WO9848000A3 WO 1998048000 A3 WO1998048000 A3 WO 1998048000A3 US 9808240 W US9808240 W US 9808240W WO 9848000 A3 WO9848000 A3 WO 9848000A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- patient
- obtaining
- cytotoxic
- cancer cells
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 201000011510 cancer Diseases 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 210000000265 leukocyte Anatomy 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71545/98A AU7154598A (en) | 1997-04-23 | 1998-04-23 | A cell strain with activated anti-cancer cytotoxic activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4460197P | 1997-04-23 | 1997-04-23 | |
US60/044,601 | 1997-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998048000A2 WO1998048000A2 (en) | 1998-10-29 |
WO1998048000A3 true WO1998048000A3 (en) | 1999-01-28 |
Family
ID=21933268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/008240 WO1998048000A2 (en) | 1997-04-23 | 1998-04-23 | A cell strain with activated anti-cancer cytotoxic activity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7154598A (en) |
WO (1) | WO1998048000A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1231262A4 (en) * | 1999-10-21 | 2004-09-08 | Keisuke Teshigawara | Method of in vitro culture of lymphocytes and gene therapy compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0690125A2 (en) * | 1994-06-28 | 1996-01-03 | The Institute Of Physical & Chemical Research | Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells |
US5484596A (en) * | 1984-01-31 | 1996-01-16 | Akzo N.V. | Active specific immunotherapy |
WO1996029394A1 (en) * | 1995-03-17 | 1996-09-26 | The Regents Of The University Of California | Method for treating tumors |
WO1998004282A1 (en) * | 1996-07-25 | 1998-02-05 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
-
1998
- 1998-04-23 WO PCT/US1998/008240 patent/WO1998048000A2/en active Application Filing
- 1998-04-23 AU AU71545/98A patent/AU7154598A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484596A (en) * | 1984-01-31 | 1996-01-16 | Akzo N.V. | Active specific immunotherapy |
EP0690125A2 (en) * | 1994-06-28 | 1996-01-03 | The Institute Of Physical & Chemical Research | Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells |
WO1996029394A1 (en) * | 1995-03-17 | 1996-09-26 | The Regents Of The University Of California | Method for treating tumors |
WO1998004282A1 (en) * | 1996-07-25 | 1998-02-05 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
Non-Patent Citations (3)
Title |
---|
J.R. SPORN ET AL.,: "Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukine", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, vol. 37, no. 3, 1993, Sttutgart, DE, pages 175 - 180, XP002081415 * |
N.J. CROWLEY ET AL.,: "Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas", CANCER RESEARCH, vol. 50, no. 1, 1990, pages 492 - 495, XP002066686 * |
R. S. YAMAMOTO ET AL.,: "Generation of stimulated, lymphokine activated T killer (T-LAK) cells from peripheral blood of normal donors and adult patients with recurrent glioblastoma", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 137, 1991, pages 225 - 235, XP002081416 * |
Also Published As
Publication number | Publication date |
---|---|
AU7154598A (en) | 1998-11-13 |
WO1998048000A2 (en) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. | |
Scala et al. | Human large granular lymphocytes are potent producers of interleukin-1 | |
Rook et al. | The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T cells | |
Patard et al. | Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review | |
Vora et al. | Antigen presentation by human dermal microvascular endothelial cells. Immunoregulatory effect of IFN-gamma and IL-10. | |
CA2046916A1 (en) | Methods and compositions for treatment of cancer using oligonucleotides | |
Matar et al. | Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide | |
Cao et al. | Keratinocytes Induce Local Tolerance to Skin Graft by Activating Interleukin-10–Secreting T Cells in the Context of Costimulation Molecule B7-H11 | |
IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
DE4410136A1 (en) | Tumoricidal T lymphocytes | |
WO1998048000A3 (en) | A cell strain with activated anti-cancer cytotoxic activity | |
Klinkert | Rat bone marrow precursors develop into dendritic accessory cells under the influence of a conditioned medium | |
EP0953351A3 (en) | Medicaments containing, as the main ingredient, allogenic activated-CD4+ cells and method for producing the same | |
Varney et al. | Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction | |
Brandau et al. | In vitro generation of bacillus Calmette-Guerin-activated killer cells | |
EP0460065B1 (en) | A process for the generation of proliferating cd4 lymphocytes | |
Tsai et al. | Effect of IFN‐γ treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine‐activated killef (LAK) cell lysis in vitro; association with H‐2 expression on the target cells | |
Sloan et al. | Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity | |
Belfrage et al. | Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity | |
US5846928A (en) | Method for treating cancer patients | |
Schneekloth et al. | Low-Dose lnterleukin-2 in Combination with Interferon-α Effectively Modulates Biological Response in vivo | |
Schöndorf et al. | Immunologic Features of Tumor-Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Overian Cancer Patients | |
Rogalski et al. | Immunomodulators in the treatment of cutaneous lymphoma | |
Huber et al. | Pteridines in the assessment of lymphocyte activation | |
Parrado et al. | Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998546352 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |